Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: telem healthassessment.
- Who it may be relevant to
- Registry conditions: Rash, Systemic Treatments, Tele-assessment. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Ireland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
Overview
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
Interventions
- Other telem healthassessment
SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders
Primary outcome measures
- time to clinical resolution [Time frame: 6 weeks]
Secondary outcome measures (4)
- Escalation in person review [Time frame: 6 weeks]
- treatment modification reat [Time frame: 6 weeks]
- unscheduled acute contact [Time frame: 6 weeks]
- Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction [Time frame: 6 weeks]
Eligibility criteria
Inclusion Criteria:Participants must meet all of the following criteria:
- Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
- New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
- Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
- Clinically stable condition not requiring urgent in-person evaluation.
- Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.
Exclusion Criteria: Participants will be excluded if any of the following criteria apply:
- Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
- Clinical status requiring urgent or immediate face-to-face medical assessment.
- Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
- Inability to access or effectively use the required telemedicine technology.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Ireland · 1 center
- Sligo university Hospital — Sligo
Identifiers
NCT: NCT07476807 · 1067SUHREC